

Key Figures 6M/2023*



ORDER INTAKE **€3,474**m
(-26.6%)¹

\$ALE\$ **€3,719**m
(+10.6%)¹

ADJ. EBIT **€207**m
(+2.5%)¹

5.6% (-0.4PP)¹

NET PROFIT **€204**m
(+15.9%)¹

FCF €**86**m 9,704

^{*} All figures are unaudited

¹ Change year-on-year

² Full-time equivalents as of June 30, 2023

Figures at a Glance 6M/2023



in € million			
	Jan. 1 - Jun. 30, 2023	Jan. 1 - Jun. 30, 2022	Growth
Order intake	3,474	4,731	-26.6%
Sales	3,719	3,363	10.6%
Gross profit	304	277	9.7%
Gross profit margin in %	8.2	8.2	0.0PP
EBIT	199	195	2.1%
EBIT margin in %	5.4	5.8	-0.4PP
Adjusted EBIT	207	202	2.5%
Adjusted EBIT margin in %	5.6	6.0	-0.4PP
Adjusted EBITDA	232	222	4.5%
Adjusted EBITDA margin in %	6.2	6.6	-0.4PP
Group net profit	204	176	15.9%
Group net profit margin in %	5.5	5.2	0.3PP
No. of Employees (full-time equivalents at the end of period)	9,704	8,572	13.2%
Cash flow from operating activities	78	479	-
Cash flow from investing activities	8	-11	-
Free cash flow	86	468	-
Order backlog (at the end of period)	6,385	8,249	-22.6%

Key Financials 6M/2023 I






- Reduced order intake in Q2/2023 due to project phasing. Strong quarters expected until year-end.
- Substantial order backlog of 6,385 Mio. € ensures future profitable sales growth.

- Continuous increase of sales due to flawless execution of large Advanced Technology Facilities (ATF) projects worldwide.
- Substantial sales development and growth also coming from Biopharma and Life Sciences (BLS), Data Centers (DTC) as well as Technology & Services (T&S).

Key Financials 6M/2023 II





 Adjusted EBIT of 6M/2023 outperformed 6M/2022 following sales growth.

 Along with the growth of adjusted EBIT, adjusted EBITDA improved to 232 Mio. € in the first six months of 2023.

Order Intake by Region 6M/2023




ORDER INTAKE BY REGION¹

In € Million

	6M/2023	
APAC	566	3,023
EMEA	2,064	905
AMER	319	459
T&S	599	552

in % of total oder intake (previous year)



HIGH ORDER INTAKE IN EMEA

- Constant shift of business from APAC to EMEA and US in ATF segment, also as a result of state subsidies in EU and US.
- T&S with strong contribution to the Group order intake.

© Exyte | Financial Statement 6M/2023 |

Order Intake by Business Segment 6M/2023




CONTINUOUS POSITIVE DEVELOPMENT IN ATF AND BLS

- ATF business segment remains largest segment with a share of around 83% of the Group order intake. Significant projects have been awarded in Germany and the US.
- Order intake of BLS business segment increased by over 30% compared to 6M/2022 mainly due to a large project in Singapore.
- Order intake of DTC developed as expected with less project awards in the first half of 2023 compared to 6M/2022. Strong quarters expected until year-end.

ORDER INTAKE BY BUSINESS SEGMENT

	6M/2023	6M/2022
ATF	2,895	4,186
BLS	368	283
DTC	124	233
RSB	87	28



© Exyte | Financial Statement 6M/2023 09/05/2023 |


Sales by Region 6M/2023



SALES BY REGION¹

In € Million

	6W/2U23	
APAC	1,853	1,862
EMEA	1,063	1,044
AMER	512	202
T&S	438	360







EXCELLENT PERFORMANCE IN ALL REGIONS

- APAC's performance remains on a high level due to large projects in execution in Asia.
- US more than doubled sales compared to 6M/2022.
- T&S successfully continuing their growth initiatives.

1) Before consolidation of the regions.

Sales by Business Segment 6M/2023




ATF CONTINUES TO BE THE MAIN GROWTH DRIVER

- 6M/2023 Sales in all three main business segments above the levels of 6M/2022.
- Due to the execution of large-scale semiconductor projects in all regions, the ATF business segment continues to grow on a year-on-year basis.
- BLS business segment increased sales slightly due to major projects in Singapore, Germany and Malaysia.
- DTC business segment more than doubled sales, mainly driven by multiple projects in Taiwan, Denmark, Israel and Malaysia.

SALES BY BUSINESS SEGMENT

	6M/2023	6M/2022
ATF	3,147	2,920
BLS	293	291
DTC	251	114
RSB	28	37



Earnings Performance 6M/2023



ADJUSTED EBIT¹

In € Million

	6M/2023	6M/2022
Reported EBIT	198.9	195.1
Adjustments	8.5	6.7
of which due to restructuring measures	1.1	1.7
of which related to depreciation of PPAs	3.8	3.2
of which other adjustments	3.6	1.8
Adjusted EBIT ¹	207.4	201.8

PROFITABILITY IMPROVED

- Increase of adjusted EBIT¹ (adjusted earnings before interest and taxes) in 6M/2023 compared to 6M/2022.
- The adjusted EBIT margin decreased to 5.6% in 6M/2023 (0.4PP lower than 6M/2022) due to project and regional mix.

© Exyte | Financial Statement 6M/2023 |

¹⁾ Adjusted EBIT is defined as the result from operating activities (earnings before interest and tax; EBIT) adjusted for income or expenses deriving from non-recurring effects. EBIT adjustments result from income or expenses related to the Exyte Group's reorganization, costs of restructuring measures, costs incurred due to site closures and relocations, effects on earnings from purchase price allocations or other income or expenses that are non-recurring in nature or are incurred outside the normal course of business, as well as COVID 19-related effects. Adjusted EBIT is used to determine profitability excluding non-recurring positive or negative effects, thus ensuring comparability between different reporting periods.

Outlook Financial Year 2023



We anticipate the global economy to continue to recover. However, we still assume that fiscal policies and geopolitical tensions will continue to have a negative impact on the overall economic development in 2023.

Due to the unchanged positive environment in the industry sectors in which we are active, we expect the 2023 order intake to be around the same high level as in the previous year. Based on the high order backlog at the end of 2022 and planned new orders, we expect a further increase in sales to around €8.0 billion in 2023.

© Exyte | Financial Statement 6M/2023 |

Disclaimer



This presentation contains forward-looking statements that reflect our current view about future business and financial performance as well as future events or developments. Forward-looking statements are characterized by the use of words such as "expect," "intend," "plan," "predict," "assume," "believe," "estimate," "anticipate," and similar expressions. These statements are based on current expectations and assumptions made by the executive management of Exyte Group and are subject to many risks and uncertainties which are mainly beyond Exyte's control. Should any of these risks or uncertainties materialize or any expectations or assumptions prove to be incorrect, the actual future results may be materially different from those described explicitly or implicitly in the relevant forward-looking statement. Therefore, Exyte does not guarantee any of these forward-looking statements and neither intends nor assumes any obligation to update or revise those in case of developments which differ from those anticipated.

Exyte Group accepts no liability for the accuracy and completeness of information provided in this presentation.

© Exyte | Financial Statement 6M/2023 09/05/2023 |

Contact



Exyte
René Ziegler
Corporate Communications & Investor Relations
Löwentorbogen 9b
70376 Stuttgart
Germany

T +49 711 8804 4606 ir@exyte.net

© Exyte | Financial Statement 6M/2023 | 09/05/2023 |